cardio may 11 national

7/31/2019 Cardio May 11 National

1/42

Cardiovascular SystemNational Charts


2/42

Cardiovascular Index of National Charts

Spending on High Strength Statins vs all other Statins42Prescribing of and Spending on Nicorandil21

Prescribing of High Strength Statins vs all other Statins41Spending on Calcium-Channel Blockers20

Prescribing of and Spending on Inegy40Prescribing of Calcium-Channel Blockers19

Spending on Rosuvastatin Tablets by Strength39Spending on Angiotensin-ll Receptor Antagonists (incl combinations)18

Prescribing of Rosuvastatin Tablets by Strength38Prescribing of Angiotensin-ll Receptor Antagonists (incl combinations)17

Spending on Simvastatin Tablets by Strength37Spending on ACE-Inhibitors (including combinations)16

Prescribing of Simvastatin Tablets by Strength36Prescribing of ACE-Inhibitors (including combinations)15

Spending on Atorvastatin Tablets by Strength35ACE Inhibitors vs Angiotensin-II Receptor Antagonists - Spending14

Prescribing of Atorvastatin Tablets by Strength34ACE Inhibitors vs Angiotensin-II Receptor Antagonists - Prescribing13

Spending on Statins33Spending on Alpha-adrenoceptor Blocking Drugs12

Prescribing of Statins32Prescribing of Alpha-adrenoceptor Blocking Drugs11

Prescribing of and Spending on Ezetimibe31Spending on Beta-adrenoceptor Blocking Drugs (including combinations)10

Spending on Lipid-regulating Drugs (excluding Statins)30Prescribing of Beta-adrenoceptor Blocking Drugs (including combinations)9

Prescribing of Lipid-regulating Drugs (excluding Statins)29Prescribing of and Spending on Amiodarone8

Spending on Aspirin BNF 2.9 (E/C Tablets vs Other Formulations)28Prescribing of Spironolactone (strengths)7

Prescribing of Aspirin BNF 2.9 (E/C Tablets vs Other Formulations)27Spending on Potassium-sparing Diuretics6

Spending on Antiplatelets26Prescribing of Potassium-sparing Diuretics5

Prescribing of Antiplatelets25Spending on Thiazides and Related Diuretics4

Prescribing of and Spending on Warfarin24

Prescribing of Thiazides and Related Diuretics3

Spending on Peripheral Vasodilators23Cardiovascular - Index of National Charts2

Prescribing of Peripheral Vasodilators22Cardiovascular1


3/42

Trends in Prescribing of Thiazides and Related Diureticsin General Practice in England

0

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

Dec-05

Mar-06

Jun-06

Sep-0

6

Dec-06

Mar-07

Jun-07

Sep-0

7

Dec-07

Mar-08

Jun-08

Sep-0

8

Dec-08

Mar-09

Jun-09

Sep-0

9

Dec-09

Mar-10

Jun-10

Sep-1

0

Dec-10

Quarter to

Item

s

Bendroflumethiazide Indapamide Others

Copyright NHSBSA 2011


4/42

Trends in Spending on Thiazides and Related Diureticsin General Practice in England

0

2,000,000

4,000,000

6,000,000

8,000,000

10,000,000

12,000,000

14,000,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

NIC

()

Bendroflumethiazide Indapamide Others



5/42

Trends in Prescribing of Potassium-sparing Diureticsin General Practice in England

0

100,000

200,000

300,000

400,000

500,000

600,000

700,000

Dec-0

5

Mar-0

6

Jun-0

6

Sep-0

6

Dec-0

6

Mar-0

7

Jun-0

7

Sep-0

7

Dec-0

7

Mar-0

8

Jun-0

8

Sep-0

8

Dec-0

8

Mar-0

9

Jun-0

9

Sep-0

9

Dec-0

9

Mar-1

0

Jun-1

0

Sep-1

0

Dec-1

0

Quarter to

Items

Spironolactone Amiloride Eplerenone Triamterene



6/42

Trends in Spending on Potassium-sparing Diureticsin General Practice in England


0

500,000

1,000,000

1,500,000

2,000,000

2,500,000

3,000,000

3,500,000

Dec-0

5

Mar-0

6

Jun-0

6

Sep-0

6

Dec-0

6

Mar-0

7

Jun-0

7

Sep-0

7

Dec-0

7

Mar-0

8

Jun-0

8

Sep-0

8

Dec-0

8

Mar-0

9

Jun-0

9

Sep-0

9

Dec-0

9

Mar-1

0

Jun-1

0

Sep-1

0

Dec-1

0

Quarter to

NIC()

Spironolactone Amiloride Eplerenone Triamterene


7/42

Trends in Prescribing of Spironolactone Caps/Tabsin General Practice in England


0

50,000

100,000

150,000

200,000

250,000

300,000

350,000

400,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

Ite

ms

25mg 50mg 100mg


8/42

Trends in Prescribing of and Spending on Amiodaronein General Practice in England


0

50,000

100,000

150,000

200,000

250,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

Ite

ms

0

100,000

200,000

300,000

400,000

500,000

600,000

700,000

800,000

900,000

1,000,000

NIC()

Items NIC ()


9/42

Trends in Prescribing of Beta-adrenoceptor Blocking Drugs(including Combinations) in General Practice in England


0

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

7,000,000

8,000,000

9,000,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

Items

Atenolol Bisoprolol Propranolol Metoprolol Sotalol

Carvedilol Nebivolol Combinations Others


10/42

Trends in Spending on Beta-adrenoceptor Blocking Drugs(including Combinations) in General Practice in England

0

5,000,000

10,000,000

15,000,000

20,000,000

25,000,000

30,000,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

N

IC()

Atenolol Bisoprolol Propranolol Metoprolol Sotalol

Carvedilol Nebivolol Combinations Others



11/42

Trends in Prescribing of Alpha-adrenoceptor Blocking Drugsin General Practice in England

0

200,000

400,000

600,000

800,000

1,000,000

1,200,000

1,400,000

1,600,000

1,800,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

Items

Doxazosin Prazosin Terazosin Others



12/42

Trends in Spending on Alpha-adrenoceptor Blocking Drugs inGeneral Practice in England

0

2,000,000

4,000,000

6,000,000

8,000,000

10,000,000

12,000,000

14,000,000

16,000,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

NIC()

Doxazosin Prazosin Terazosin Others



13/42

% of Prescribing of ACE Inhibitors vs Angiotensin-II Receptor Antagonistsin General Practice in England


0%

20%

40%

60%

80%

100%

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

%o

fallitems

ACE Inhibitors Angiotensin-II Receptor Antagonists


14/42

% of Spending on ACE Inhibitors vs Angiotensin-II Receptor Antagonistsin General Practice in England


0%

20%

40%

60%

80%

100%

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

%o

fN

IC()

ACE Inhibitors Angiotensin-II Receptor Antagonists


15/42

Trends in Prescribing of ACE Inhibitors (including combinations)in General Practice in England


0

2,000,000

4,000,000

6,000,000

8,000,000

10,000,000

12,000,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

Items

Ramipril Lisinopril Perindopril Enalapril Combinations Others


16/42

Trends in Spending on ACE Inhibitors (including combinations)in General Practice in England

0

10,000,000

20,000,000

30,000,000

40,000,000

50,000,000

60,000,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

NIC()

Ramipril Lisinopril Perindopril Enalapril Combinations Others



17/42

Trends in Prescribing of Angiotensin-II Receptor Antagonists(including combinations) in General Practice in England

0

500,000

1,000,000

1,500,000

2,000,000

2,500,000

3,000,000

3,500,000

4,000,000

4,500,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

Ite

ms

Candesartan Losartan Irbesartan Valsartan Olmesartan Combinations Others



18/42

Trends in Spending on Angiotensin-II Receptor Antagonists(including combinations) in General Practice in England

0

10,000,000

20,000,000

30,000,000

40,000,000

50,000,000

60,000,000

70,000,000

80,000,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

N

IC()

Candesartan Losartan Irbesartan Valsartan Olmesartan Combinations Others



19/42

Trends in Prescribing of Calcium-channel Blockersin General Practice in England

0

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

7,000,000

8,000,000

9,000,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

Items

Amlodipine Felodipine Nifedipine

Diltiazem Lercanidipine Verapamil

Others



20/42

Trends in Spending on Calcium-channel Blockersin General Practice in England

0

10,000,000

20,000,000

30,000,000

40,000,000

50,000,000

60,000,000

70,000,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

NIC

()

Amlodipine Felodipine Nifedipine

Diltiazem Lercanidipine Verapamil

Others



21/42

Trends in Prescribing of and Spending on Nicorandilin General Practice in England

0

100,000

200,000

300,000

400,000

500,000

600,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

Items

0

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

7,000,000

N

IC()

Items NIC



22/42

Trends in Prescribing of Peripheral Vasodilators and Related Drugsin General Practice in England

0

10,000

20,000

30,000

40,000

50,000

60,000

70,000

80,000

90,000

Dec-05

Mar-06

Jun-06

Sep-0

6

Dec-06

Mar-07

Jun-07

Sep-0

7

Dec-07

Mar-08

Jun-08

Sep-0

8

Dec-08

Mar-09

Jun-09

Sep-0

9

Dec-09

Mar-10

Jun-10

Sep-1

0

Dec-10

Quarter to

It

ems

Naftidrofuryl Oxalate Oxerutins Cilostazol Pentoxifylline Nicotinic Acid Derivatives Others



23/42

Trends in Spending on Peripheral Vasodilators and Related Drugsin General Practice in England

0

200,000

400,000

600,000

800,000

1,000,000

1,200,000

1,400,000

1,600,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

NIC

()

Naftidrofuryl Oxalate Oxerutins Cilostazol Pentoxifylline Nicotinic Acid Derivatives Others



24/42

Trends in Prescribing of and Spending on Warfarinin General Practice in England

0

500,000

1,000,000

1,500,000

2,000,000

2,500,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

Items

0

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

7,000,000

NIC()

Items NIC ()


T d i P ibi f A i l l D


25/42

Trends in Prescribing of Antiplatelet Drugsin General Practice in England

0

2,000,000

4,000,000

6,000,000

8,000,000

10,000,000

12,000,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

Items

Aspirin Clopidogrel Dipyridamole Others


T d i S di A ti l t l t D


26/42

Trends in Spending on Antiplatelet Drugsin General Practice in England

0

10,000,000

20,000,000

30,000,000

40,000,000

50,000,000

60,000,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

NIC()

Aspirin Clopidogrel Dipyridamole Others

N.B The price held for Dipyridamole 200mg m/r caps was incorrect during the quarter to December 2009,which accounts for the inflated NIC for this period


Trends in Prescribing of Aspirin BNF 2.9


27/42

g p(E/C Tablets vs Other Formulations)

in General Practice in England

0

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

7,000,000

8,000,000

9,000,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

Items

Others E/C


Trends in Spending on Aspirin BNF 2.9


28/42

p g p(E/C Tablets vs Other Formulations)


0

2,000,000

4,000,000

6,000,000

8,000,000

10,000,000

12,000,000

14,000,000

16,000,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

N

IC()

Others E/C


Trends in Prescribing of Lipid-regulating Drugs (excluding Statins)


29/42

Trends in Prescribing of Lipid-regulating Drugs (excluding Statins)in General Practice in England


0

100,000

200,000

300,000

400,000

500,000

600,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

Items

Omega-3 Bezafibrate Fenofibrate Ciprofibrate Colestyramine Others

NB. Excluding Ezetimibe

Trends in Spending on Lipid-regulating Drugs (excluding Statins)


30/42

Trends in Spending on Lipid-regulating Drugs (excluding Statins)in General Practice in England

0

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

7,000,000

8,000,000

9,000,000

10,000,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

N

IC()

Omega-3 Bezafibrate Fenofibrate Ciprofibrate Colestyramine Others

NB. Excluding Ezetimibe


Trends in Prescribing of and Spending on Ezetimibe


31/42

Trends in Prescribing of and Spending on Ezetimibein General Practice in England

0

100,000

200,000

300,000

400,000

500,000

600,000

700,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

Ite

ms

0

5,000,000

10,000,000

15,000,000

20,000,000

25,000,000

NIC

()

Items NIC ()


T d i P ibi f St ti i G l P ti i E l d


32/42

Trends in Prescribing of Statins in General Practice in England

0

2,000,000

4,000,000

6,000,000

8,000,000

10,000,000

12,000,000

14,000,000

16,000,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

Items

Simvastatin Atorvastatin Pravastatin Rosuvastatin Others


T d i S di g St ti i G l P ti i E gl d


33/42

Trends in Spending on Statins in General Practice in England

0

50,000,000

100,000,000

150,000,000

200,000,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

NIC()

Simvastatin Atorvastatin Pravastatin Rosuvastatin Others


Trends in Prescribing of Atorvastatin Tablets by Strength


34/42

g y gin General Practice in England

0

200,000

400,000

600,000

800,000

1,000,000

1,200,000

1,400,000

1,600,000

1,800,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

I

tems

10mg 20mg 40mg 80mg


Trends in Spending on Atorvastatin Tablets by Strength


35/42


0

5,000,000

10,000,000

15,000,000

20,000,000

25,000,000

30,000,000

35,000,000

40,000,000

45,000,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

N

IC()

10mg 20mg 40mg 80mg


Trends in Prescribing of Simvastatin Tablets by Strength


36/42


0

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

7,000,000

8,000,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

Items

10mg 20mg 40mg 80mg


Trends in Spending on Simvastatin Tablets by Strength


37/42



0

5,000,000

10,000,000

15,000,000

20,000,000

25,000,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

NIC()

10mg 20mg 40mg 80mg

Trends in Prescribing of Rosuvastatin Tablets by Strengthi G l P i i E l d


38/42



0

50,000

100,000

150,000

200,000

250,000

300,000

350,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

Items

5mg 10mg 20mg 40mg

Trends in Spending on Rosuvastatin Tablets by Strengthi G l P ti i E l d


39/42



0

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

7,000,000

8,000,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

NIC()

5mg 10mg 20mg 40mg

Trends in Prescribing of and Spending on Inegyin General Practice in England


40/42


0

10,000

20,000

30,000

40,000

50,000

60,000

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

Items

0

500,000

1,000,000

1,500,000

2,000,000

2,500,000

3,000,000

NIC()

Items NIC


% of Prescribing of High Strength Statins (Atorvastatin 40mg / 80mg,Rosuvastatin 20mg / 40mg, Simvastatin 80mg and Inegy)


41/42

g g g gyvs All Other Statins in General Practice in England

0%

20%

40%

60%

80%

100%

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

%o

fItems

All other Statins High Strength


% of Spending on High Strength Statins (Atorvastatin 40mg / 80mg,Rosuvastatin 20mg / 40mg, Simvastatin 80mg and Inegy)


42/42

vs All Other Statins in General Practice in England

0%

20%

40%

60%

80%

100%

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Dec-08

Mar-09

Jun-09

Sep-09

Dec-09

Mar-10

Jun-10

Sep-10

Dec-10

Quarter to

%o

fNIC()

All other Statins High Strength


cardio may 11 national

Documents